Get started
Inventiva SA ADRInventiva SA ADRInventiva SA ADR

Inventiva SA ADR

No trades
See on Supercharts
OverviewFinancialsNewsDiscussionsForecastSeasonals

6IVA chart


Full chart

6IVA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪674.04 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.46 EUR
Net income (FY)
‪−192.48 M‬ EUR
Revenue (FY)
‪9.61 M‬ EUR
Shares float
‪136.98 M‬
Beta (1Y)
−0.09

About Inventiva SA


Sector
Health Technology
Industry
Biotechnology
CEO
Frédéric Cren
Website
inventivapharma.com
Headquarters
Daix
Founded
2011
ISIN
US46124U1079
FIGI
BBG00VYK2907
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Check out other big names from the same industry as 6IVA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

6IVA news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.